Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III randomized double-blind placebo-controlled study of ICA-17043 in sickle cell disease
2004-004617-42Phase 3Completed
- Sponsor
- Icagen
- Start
- May 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of senicapoc in sickle cell disease (SCD) (4 arms), sponsored by Icagen. Primary endpoint: Rate of acute sickle-related painful crises. Started May 2005; status: completed.
02
Drugs
senicapoc
03
Conditions
sickle cell disease (SCD)
Beyond the preview
Go deeper on 2004-004617-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-004617-42.